Dx Firms Should Measure Patient Outcomes During Pivotal Trials – Consultant
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic firms aiming to conduct a single trial to satisfy both FDA and CMS requirements could examine patient outcomes retrospectively, according to Eleanor Perfetto, PhD, The Weinberg Group